A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD-1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

doi:10.1002/hed.70313

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD-1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Head & neck - 1 Oct 2026

Fiedler Mathias, Baumann Lea, Eichberger Jonas, Gottsauner Maximilian, Schuderer Johannes G, Schulz Daniela, Meier Johannes K, Bauer Richard J, Poeck Hendrik, Grube Matthias, Gerken Michael, Reichert Torsten E, Weber Florian, Ettl Tobias

Abstract excerpt

BACKGROUND: Predictive biomarkers for response to PD-1 blockade in recurrent or metastatic HNSCC remain limited. We investigated whether coordinated expression of multiple inhibitory immune checkpoints defines a clinically relevant biomarker phenotype. METHODS: Clinical and immunohistochemical data from 78 patients with recurrent or metastatic HNSCC treated with nivolumab or pembrolizumab were retrospectively...

Read the complete abstract on PubMed

Topics

Humans
Female
Male
Retrospective Studies
Head and Neck Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Immune Checkpoint Inhibitors

Squamous Cell Carcinoma of Head and Neck

Neoplasm Recurrence, Local

Phenotype

Middle Aged

Aged

Antibodies, Monoclonal, Humanized

Programmed Cell Death 1 Receptor

Nivolumab

Biomarkers, Tumor

Adult

Source

Open in PubMed

Identifiers

PMID: 42108192
DOI: 10.1002/hed.70313

Genes

IDO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD-1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.PMID 42108192Read ↗

PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.Semantic proximity Read ↗

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapiesSemantic proximity Read ↗

Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.Semantic proximity Read ↗

Heterogeneity of PD-L1 expression on tumor cells and tumor-infiltrating immune cells between the primary tumor and matched lymph node metastases in head and neck squamous cell carcinomasSemantic proximity Read ↗

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneitySemantic proximity Read ↗

Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT StudySemantic proximity Read ↗

Integrated Histopathology–Transcriptomic Biomarker Enhances Survival Prediction in HNSCC Patients Treated with ImmunotherapySemantic proximity Read ↗

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factorsSemantic proximity Read ↗

Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinomaSemantic proximity Read ↗

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer respondersSemantic proximity Read ↗

Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.